CDK4/6 inhibitors, which were prevalent in metastatic breast cancer, have expanded their scope to early breast cancer. Following Lily Verzenio, Novartis Kisqali demonstrated the effect of adjuvant therapy after surgery through a clinical presentation this year. As the role of CDK4/6 inhibitors expands, new concerns are emerging to achieve the best cost-effectiveness.

Joo-Hyeok Son, a professor of oncology at Yonsei Cancer Hospital, who met at the 'American Society of Clinical Oncology Annual Conference (ASCO 2023)' held for five days from the 2nd (local time) said, "The risk ratio (HR) of Verzenio is slightly higher than the risk ratio (HR) shown in early breast cancer. However, as time goes on, it rema